Search results
Results from the WOW.Com Content Network
Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months. Despite a string of solid earnings reports from the biotechnology giant ...
Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially considering that the market ...
On Tuesday, Amgen Inc. (NASDAQ:AMGN) reported second-quarter sales of $8.39 billion, up 20% year over year and beating the consensus of $8.33 billion. Product sales grew 20%, driven by 26% volume ...
Amgen (AMGN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
For premium support please call: 800-290-4726 more ways to reach us
Amgen (AMGN) closed the most recent trading day at $246.63, moving -0.28% from the previous trading session.
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before ...
Let's see if Amgen (AMGN) stock is a good choice for value-oriented investors right now from multiple angles.